Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluoroethylcholine→

Fluoroethylcholine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
C7H17FNO+
Molecular weight
150.21 g/mol
Drug class
Diagnostic radiopharmaceuticalfluorine-18-labelled choline analogue for PET imaging
Mechanism of action
Enters tumour cells through carrier-mediated choline transport, is phosphorylated intracellularly by choline kinase and can be incorporated into membrane phospholipids. Increased choline uptake and phosphorylation in proliferating tumour cells provide a PET imaging signal.
Indications / reported uses
  • Investigational or specialised PET imaging of prostate cancer and other tumours; clinical use depends on local tracer preparation, validation and authorisation.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluoroethylcholine · https://pubmed.ncbi.nlm.nih.gov/11850483/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluoroethylcholine Environmental Risk Assessment (ERA) (the Fluoroethylcholine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.